Some staff at Elon Musk’s Neuralink are preparing to sell shares after the brain implant company’s valuation surged following its first human trial, according to sources. Stock compensation is a key incentive for employees at startups like Neuralink. The shares are not publicly traded, and selling them privately requires navigating niche market exchanges.
Sources say Neuralink plans to launch a tender offer next month to buy back shares from employees. The valuation jump was evident after January’s trial, with some trades suggesting a value of $8 billion, more than double last year’s worth. Neuralink called the trial a success and is preparing for more trials in Britain and Canada.
Last fall, Neuralink’s tender offer priced shares at $19 each, despite some secondary market trades at $35. Musk’s other startups, like SpaceX and xAI, also create scarcity for shares, making them highly sought after.